Prospective Study on the Incidence of Cerebrovascular Disease After Coronary Angiography

Akihiro Tokushige1, Masaaki Miyata1, Takeshi Sonoda1, Ippei Kosedo1, Daisuke Kanda1, Takuro Takumi1, Yuichi Kumagae2, Yoshihiko Fukukura2 and Mitsuru Ohishi1

1Department of Cardiovascular Medicine and Hypertension, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan
2Department of Radiology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan

Aim: Previous studies have reported a 10.2%–22% rate of silent cerebral infarction and a 0.1%–1% rate of symptomatic cerebral infarction after coronary angiography (CAG). However, the risk factors of cerebral infarction after CAG have not been fully elucidated. For this reason, we investigated the incidence and risk factors of CVD complications within 48 h after CAG using magnetic resonance imaging (MRI) (Diffusion-weighted MRI) at Kagoshima University Hospital.

Methods: From September 2013 to April 2015, we examined the incidence and risk factors, including procedural data and patients characteristics, of cerebrovascular disease after CAG in consecutive 61 patients who underwent CAG and MRI in our hospital.

Results: Silent cerebral infarction after CAG was observed in 6 cases (9.8%), and they should not show any neurological symptoms of cerebral infarction. Only prior coronary artery bypass grafting (CABG) was more frequently found in the stroke group (n=6) than that in the non-stroke group (n=55); however, no significant difference was observed (P=0.07). After adjusting for confounders, prior CABG was a significant independent risk factor for the incidence of stroke after CAG (odds ratio: 11.7, 95% confidence interval: 1.14–129.8, P=0.04).

Conclusions: We suggested that the incidence of cerebral infarction after CAG was not related to the catheterization procedure per se but may be caused by atherosclerosis with CABG.

See editorial vol. 25: 221-223

Key words: Cerebral infarction, Coronary angiography, Magnetic resonance imaging

Copyright©2018 Japan Atherosclerosis Society
This article is distributed under the terms of the latest version of CC BY-NC-SA defined by the Creative Commons Attribution License.

Introduction

The magnitude of cerebrovascular disease (CVD) related to coronary catheterization is high and sometimes severe. It is considered one of the most severe complications after coronary angiography (CAG). We have observed the occurrence of CVD complications after percutaneous coronary intervention (PCI) as well as after the only examination technique such as CAG.

Although the frequency of symptomatic CVD complications was explained to patients filling the catheter examination consent form at our facility, the frequency of asymptomatic CVD complications was not explained completely in the real clinical practice because it has not been substantially investigated.

Previous studies have reported the rate of symptomatic CVD complications after CAG and PCI to be 0.1%–1%1-3 and 0.1%–0.6%4-9, respectively. However, the rate of asymptomatic CVD is 10.2%–22%, which is significantly higher than that of symptomatic CVD10-13. In addition, there are multiple risk factors of CVD after PCI and CAG including advanced age, hypertension, diabetes mellitus (DM), prior stroke, and the use of intra-aortic balloon pumping (IABP)9, 13-16. It has been shown that CVD after CAG or PCI is
associated with a poor prognosis. Recently, cardiac catheterization has shifted from the femoral artery to the radial artery approach, and slender catheters such as 4 Fr or 5 Fr catheters are commonly used. In addition, because of the aging Japanese population, CAG and PCI are being performed even in those aged ≥75 years. Because few studies have reported on the relationship between CVD complications after CAG or PCI and the procedural data such as puncture site, dosage of contrast medium, procedure time, catheter size, CVD complication risks remains unknown in Japan. Therefore, we investigated the incidence and risk factors of CVD complication within 48 h after CAG using diffusion-weighted magnetic resonance imaging (DW-MRI) at our institute.

Methods

Subjects and Study Protocol

We conducted a prospective study including patients who underwent CAG and were admitted to Kagoshima University Hospital between September 2013 and April 2015. In the patients who underwent several CAG, the first CAG was used in this study. Patients who corresponded to MRI exclusion criteria and were considered inappropriate by the physician were excluded from the study. The patients underwent MRI of their heads within 48 h after CAG, with or without symptoms, and MRI interpretation was performed immediately by a radiologist in a blinded manner.

All patients gave their written informed consent prior to participating in the study and were the subjects of this analysis. This study complied with the standards of the Declaration of Helsinki and current ethical guidelines, and it was approved by the institutional ethics board at Kagoshima University Hospital. Maximum effort was taken by all involved in this study to ensure anonymity and protection of subject information. We referred to the case identification cord instead of the medical record number of each subject.

Coronary Angiography

CAG was performed by well-trained cardiologists according to the standardized Judkins method. All patients underwent CAG using 4 to 6 Fr catheters via femoral or radial access, as selected based on the operator’s judgment. In addition, we did not perform the left ventricle (LV) graphy routinely in the patients with aortic stenosis because there is a possibility of high rate of CVD complications. Before starting the procedure, patients were administered 3000 U of unfractionated heparin intravenously. A non-ionic iso-osmolar contrast medium was used during CAG. The total fluoroscopy time was measured in all cases.

Measurements

Blood specimens for the measurement of BNP and lipoprotein (a) levels were collected at the time of admission. A blood sample for the measurement of Cystatin C was collected before CAG.

Hypertension was defined as having systolic blood pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg, or by the use of antihypertensive drugs. DM was defined as having an HbA1c level of ≥6.5%, or occasionally, a blood glucose level of ≥200 mg/dL, fasting blood glucose level of ≥126 mg/dL, or a history of treatment for diabetes. Dyslipidemia was defined as having a low-density lipoprotein cholesterol level of ≥140 mg/dL, triglyceride level of ≥150 mg/dL, high-density lipoprotein cholesterol level of ≤40 mg/dL, or the use of lipid-lowering drugs such as statin and fibrates. CAD was defined as a diameter stenosis of the presence of ≥1 vessel with ≥70% luminal diameter narrowing, as detected by CAG during the present study or previous CAG by the American College of Cardiology/American Heart Association for lesion classification in three coronary arteries. Prior heart failure was defined as having a principal discharge diagnosis of heart failure. Aortic stenosis was defined as mild or over, and aortic regurgitation was defined as trace or over, according to the guidelines.

MRI

DW-MRI of the brain [1.5- or 3-Tesla (T) Achieva Nova Dual, Philips Medical Systems, Netherlands] was performed within 48 h after CAG. The imaging protocol included DW single-shot spin echo-planar imaging [repetition time (TR): 4500 ms (1.5-T), 4000 ms (3-T); echo time (TE): 74 ms (1.5-T), 87 ms (3-T); slice thickness: 5 mm (1.5-T and 3-T); interslice gap: 1 mm (1.5-T and 3-T); 24 axial slices (1.5-T and 3-T); matrix: 102×128 (1.5-T and 3-T); field view: 220 mm (1.5-T and 3-T); diffusion gradient: b values of 0 and 1000 s/mm² (1.5-T and 3-T, respectively)], fluid-attenuated inversion recovery [TR/TE/inversion time (TI): 9000/119/2500 ms (1.5-T), 9000/123/2500 ms (3-T)], and T2- weighted turbo spin echo [TR/TE: 4000/89 (1.5-T), 4000/87 ms (3-T)] sequences. All MRI findings were analyzed by 2 radiologists in a blinded manner. We diagnosed acute embolic infarction using the combination of DW and apparent diffusion coefficient (ADC) map findings.

Statistical Analysis

Descriptive statistics are presented as frequency (percentage) for categorical variables and mean ± standard deviation or median (interquartile range) for continuous variables. The data were compared using a chi-square or Fisher’s exact test for a categorical vari-
Table 1. Baseline Characteristics of Patients with (CVD) and without (non-CVD) Stroke after CAG

| Variables                                   | All patients | CVD  | non-CVD | P value |
|---------------------------------------------|--------------|------|---------|---------|
| (A) Clinical characteristics                |              |      |         |         |
| Age (years)                                 | 70.0 ± 10.2  | 65.5 ± 4.2 | 70.5 ± 1.4 | 0.3     |
| Age ≥ 75 years                               | 23 (38%)     | 1 (17%) | 22 (40%) | 0.4     |
| Male                                        | 43 (70%)     | 3 (50%)  | 40 (73%) | 0.3     |
| BMI                                         | 23.9 ± 4.0   | 23.8 ± 1.6 | 23.9 ± 0.5 | 0.97    |
| BMI < 25.0                                   | 36 (59%)     | 3 (50%)  | 33 (60%) | 0.7     |
| Hypertension                                | 44 (72%)     | 3 (50%)  | 41 (75%) | 0.3     |
| Diabetes mellitus                           | 25 (41%)     | 1 (17%)  | 24 (44%) | 0.4     |
| Dyslipidemia                                | 41 (67%)     | 5 (83%)  | 36 (65%) | 0.7     |
| Current smoking                             | 11 (18%)     | 1 (17%)  | 10 (18%) | 1.0     |
| Prior Heart failure                         | 8 (13%)      | 1 (17%)  | 7 (13%)  | 1.0     |
| Coronary artery disease                     | 43 (70%)     | 4 (67%)  | 39 (71%) | 1.0     |
| Multi-vessel disease                        | 19 (31%)     | 3 (50%)  | 16 (29%) | 0.4     |
| Aortic stenosis                             | 7 (11%)      | 1 (17%)  | 6 (11%)  | 0.5     |
| Aortic regurgitation                         | 22 (36%)     | 3 (50%)  | 19 (35%) | 0.7     |
| Mitral regurgitation grade ≥ 3               | 8 (13%)      | 1 (17%)  | 7 (13%)  | 1.0     |
| Ejection fraction                           | 61.4 (48.5–69) | 58.5 (50.5–68.3) | 62 (47.9–74.5) | 0.7     |
| Ejection fraction < 40%                     | 6 (9.8%)     | 1 (17%)  | 5 (9.1%) | 0.5     |
| Prior PCI                                    | 28 (46%)     | 2 (33%)  | 26 (47%) | 0.7     |
| Prior CABG                                   | 5 (8.2%)     | 2 (33%)  | 3 (5.5%) | 0.07    |
| Prior myocardial infarction                 | 14 (23%)     | 1 (17%)  | 13 (24%) | 1.0     |
| Prior stroke                                | 6 (9.8%)     | 0 (0%)   | 6 (11%)  | 1.0     |
| Aortic aneurysm/dissection                  | 9 (1.8%)     | 1 (17%)  | 8 (15%)  | 1.0     |
| Peripheral vascular disease                 | 9 (1.8%)     | 1 (17%)  | 8 (15%)  | 1.0     |
| eGFR < 60, not on dialysis                  | 18 (30%)     | 1 (17%)  | 17 (31%) | 0.7     |
| Dialysis                                    | 2 (3.2%)     | 1 (17%)  | 1 (1.8%) | 0.2     |
| Atrial fibrillation                         | 5 (8.2%)     | 0 (0%)   | 5 (9.1%) | 1.0     |
| Anemia (Hb < 11.0 g/dL)                     | 10 (16%)     | 1 (17%)  | 9 (16%)  | 1.0     |
| Platelets < 100 × 10³/L                     | 1 (1.6%)     | 0 (0.0%) | 1 (1.8%) | 1.0     |
| COPD                                        | 5 (8.2%)     | 0 (0.0%) | 5 (9.1%) | 1.0     |
| Liver hepatitis                             | 2 (3.2%)     | 0 (0.0%) | 2 (3.6%) | 1.0     |
| Malignancy                                  | 7 (11%)      | 0 (0%)   | 7 (13%)  | 1.0     |
| mean PWV                                    | 1785 ± 463   | 1994 ± 973 | 1762 ± 378 | 0.6     |
| mean CAV                                    | 8.8 ± 1.6    | 8.0 ± 1.2 | 8.9 ± 1.6 | 0.2     |
| BNP                                         | 52.6 (26.4–111.6) | 56.5 (41.6–712.6) | 52.6 (26–109.4) | 0.5     |
| Lp (a)                                      | 15.4 (6.5–32.5) | 14.4 (5.6–29.6) | 15.4 (6.5–33) | 0.8     |
| Cystatin C                                  | 1.08 (0.93–1.3) | 1.09 (0.82–2.7) | 1.08 (0.93–1.3) | 0.9     |
| (B) Baseline Medications                    |              |      |         |         |
| Antiplatelet therapy                        |              |      |         |         |
| Thienopyridine                              | 36 (59%)     | 3 (8.3%) | 33 (92%) | 0.7     |
| Ticlopidine                                 | 7 (11%)      | 0 (0%)  | 7 (13%)  | 1.0     |
| Clopidogrel                                 | 29 (48%)     | 3 (50%)  | 26 (47%) | 1.0     |
| Aspirin                                     | 46 (75%)     | 5 (83%)  | 41 (75%) | 1.0     |
| Cilostazol                                  | 1 (1.6%)     | 0 (0%)  | 1 (1.8%) | 1.0     |
able, a two-sample $t$-test for normal distribution, or the Wilcoxon rank sum test for non-normal distribution of continuous variables. 95% confidence interval (CI) of binominal proportions was calculated using the adjusted Wald method\(^\text{19}\). A multiple logistic regression model was used to assess CVD risk factor complications that were expressed as odds ratios with a 95% CI, and adjusted by which a dummy variable was the advanced age assigned 75 years old and more as 1. All analyses were conducted using JMP 12.0 (SAS Institute Inc, Cary, NC). All statistical analyses were two-tailed, and $P$ value $< 0.05$ was considered statistically significant.

Results

Baseline Characteristics

The baseline characteristics of the patients are shown in Table 1. The mean age was 70.0 $\pm$ 10.2 years, and 43 (70%) patients were male. Of the 61 patients, 25 (41%) presented with DM, 41 (67%) with dyslipidemia, 44 (72%) with hypertension, and 5 (8.2%) with atrial fibrillation. 28 (46%) patients underwent PCI and 5 (8.2%) underwent CABG. In addition, 14 (23%) patients had prior myocardial infarction. In terms of procedural characteristics, a catheter size of <5 Fr was frequently used (67%), mean procedural time was 66.5 $\pm$ 19.9 min, and 10 (16%) patients underwent CAG via the femoral artery. Ergonovine provocation test was performed in 9 patients (15%), angiography of the internal mammary arteries (IMA) was performed in 1 patient (1.6%), and angiography of the saphenous vein was not done at all. Additionally, LV graphy was performed in 4 (6.6%) patients (Table 2). Regarding baseline medications, no significant difference was observed in the use of antiplatelet drugs, statins, beta-blockers, warfarin, or direct oral anticoagulants (DOAC).

The Incidence and Location of CVD Complications

The incidence of asymptomatic cerebral infarction (CI) complication after CAG was 9.8% (6 cases), with a mid-point percentage 11.1% (95% Confidence Interval: 4.3%–20.2%) calculated using the adjusted Wald method. Symptomatic cerebral infarction or symptomatic and asymptomatic cerebral hemorrhage was not observed. There were 2 cases (case 1 and 6) with an infarct lesion size $<3$ mm. Table 3 shows the location of stroke and procedural data of CAG in each patient with asymptomatic stroke after CAG. Fig. 1 shows MRI images of each patient with stroke after CAG. Only case 3 developed a cerebral infarct at two sites, whereas other cases presented with a cerebral infarct at only one site. Only one case underwent CAG via the right femoral approach, whereas the approach site of other cases was via the right radial artery. No cases underwent any IMA angiography and IABP, which were reported as risk factors of CVD after CAG or PCI.

Baseline Characteristics: CVD Group vs. Non-CVD Group

We compared the baseline characteristics of patients...
sis after adjusting for age, sex, and prior CABG to identify the independent risk factors for CVD complications after CAG, because age and sex are the important meaningful factor in the clinical practice and only prior CABG was tended to be more frequently in the CVD group than in the non-CVD group. Our results demonstrated that prior CABG was a significant independent risk factor for the incidence of stroke after CAG (OR: 11.7, 95%CI: 1.14–129.8, $P=0.04$) (Table 4).

**Discussion**

The incidence of asymptomatic CI complications after CAG was 9.8% (6 cases); however, symptomatic or asymptomatic cerebral hemorrhage was not observed. In addition, prior CABG was a significant independent risk factor for the incidence of stroke after CAG, after adjusting for age and sex.

### Table 2. Procedural Characteristics of Patients with (CVD) and without (non-CVD) Stroke after CAG

| Variables                        | All patients $N=61$ | CVD $N=6$ | non-CVD $N=55$ | $P$ value |
|----------------------------------|---------------------|-----------|----------------|-----------|
| Dose of Heparin >3000 U          | 2 (3.3%)            | 0 (0%)    | 2 (3.6%)       | 1.0       |
| Procedural time (min)            | 66.5 ± 19.9         | 61.3 ± 12.9 | 67.1 ± 20.5 | 0.5       |
| Dosage of contrast medium        | 68.8 ± 34.8         | 55.8 ± 26.2 | 70.3 ± 35.4 | 0.3       |
| Femoral artery catheterization   | 10 (16%)            | 1 (17%)   | 9 (16%)        | 1.0       |
| EM provocation                   | 9 (15%)             | 1 (17%)   | 8 (15%)        | 1.0       |
| SVG angiography                  | 0 (0%)              | 0 (0%)    | 0 (0%)         | –         |
| IMA angiography                  | 1 (1.6%)            | 0 (0%)    | 1 (1.8%)       | 1.0       |
| LV graphy                        | 4 (6.6%)            | 0 (0%)    | 4 (7.3%)       | 1.0       |

CAG = coronary angiography, EM = ergonovine malate, IMA = internal mammary artery, LV = left ventricle, and SVG = saphenous vein graft.

### Table 3. Location of Stroke and Procedural Data from each patient with Stroke after CAG

| Case No. | Location of stroke | Diagnosis after CAG | Age | Sex | Ergonovine test | Catheter size (Fr) | Heparin (U) | Procedural time (min) | Contrast medium (mL) | Access site |
|----------|--------------------|---------------------|-----|-----|-----------------|-------------------|-------------|----------------------|----------------------|-------------|
| 1        | left corona radiata| Vasospastic angina  | 68  | F   | present         | 5                 | 3000        | 75                   | 60                   | right radial |
| 2        | splenium of corpus callosum| Silent myocardial ischemia | 61  | M   | absent          | 6                 | 3000        | 73                   | 60                   | right radial |
| 3        | right thalamus and right parietal lobe| Unstable angina | 65  | M   | present         | 4                 | 3000        | 50                   | 100                  | right radial |
| 4        | right cerebellar hemisphere| Aortic regurgitation | 52  | F   | absent          | 5                 | 3000        | 55                   | 50                   | right femoral |
| 5        | right frontal lobe | Abdominal aortic aneurysm | 65  | M   | absent          | 4                 | 3000        | 70                   | 20                   | right radial |
| 6        | left cerebellar hemisphere| Silent myocardial ischemia | 82  | F   | absent          | 4                 | 3000        | 45                   | 45                   | right radial |

CAG = coronary angiography, IMA = internal mammary artery, and SVG = saphenous vein graft.

with (CVD group, $n=6$) and without (non-CVD group, $n=55$) CVD complications.

Age, sex, DM, dyslipidemia, hypertension, multivessel disease, aortic stenosis, ejection fraction, prior myocardial infarction, and atrial fibrillation were similar between CVD and non-CVD groups. In addition, regarding procedural data, there was no significant difference in catheter size, heparin dosage, procedural time, access site, and LV graphy between both groups.

In terms of medication, no significant difference was observed in the use of antiplatelet drugs, warfarin, and DOAC. Prior CABG was more frequently found in the CVD group (2/6 cases, 33%) than that in the non-CVD group (3/55 cases, 5.5%); however, no significant difference was observed ($P=0.07$).

### Independent Risk Factors for CVD Complications

We performed a multiple logistic regression analysis after adjusting for age, sex, and prior CABG to identify the independent risk factors for CVD complications after CAG, because age and sex are the important meaningful factor in the clinical practice and only prior CABG was tended to be more frequently in the CVD group than in the non-CVD group. Our results demonstrated that prior CABG was a significant independent risk factor for the incidence of stroke after CAG (OR: 11.7, 95%CI: 1.14–129.8, $P=0.04$) (Table 4).
Previous studies have reported a 10.2%–22% incidence of asymptomatic CI after CAG\textsuperscript{11, 13, 20}. Omran et al. reported a significantly high incidence rate (22%) of CI after retrograde catheterization of the aortic valve\textsuperscript{11}. Recently, Morita et al. reported that of the 84 patients who underwent MRI after catheterization, acute CI was found in 27 (32.1%) patients and the rate of CI after catheterization was significantly higher than other studies. However, because this study was a retrospective analysis and MRI was not performed for the series of catheterization procedures, the rate of CI may have been considerably overestimated\textsuperscript{21}. In Korea, the incidence of asymptomatic CI after CAG performed before CABG and detected by MRI was 10.2% (20/197 patients), with IMA angiography as the independent risk factor\textsuperscript{13}. We speculated that the incidence of stroke after PCI increased slightly compared with that after CAG because of the increase in time and complexity of the procedure. In an analysis of 9662 patients who underwent PCI, the incidence of symptomatic stroke after the procedure was 0.38% and the risk factors included the use of IABP, advanced age (>80 years), and vein graft intervention\textsuperscript{25}. A prospective study in Germany reported that 7 (15%) of 48 patients exhibited 9 focal CI after cardiac catheterization, with duration of the procedure as an independent predictor of CI occurrence\textsuperscript{10}. IMA angiography is commonly performed both before and after CABG to confirm the presence and location. Similarly, vein graft angiography is usually performed after CABG. Therefore, patients who underwent IMA angiography and vein graft angiography either before or after CABG may have severe arteriosclerosis with multiple coronary stenosis. The performance of IMA angiography and vein graft after CABG decreased because the presence and location of IMA and vein graft were confirmed by CT-angiography instead of catheterization. Because the performance of IMA and saphenous vein graft (SVG) angiography was very low in this study, a significant difference between CVD and non-CVD groups was not observed. Therefore, we speculate that it is reasonable to consider prior CABG as a significant independent risk factor for the incidence of CI after CAG.

The complications of postprocedural CVD in CAG and PCI have been reported to be caused by thrombus formation in the catheter itself and lumen, attachment of the thrombus to the exchange wire, air embolisms, and debris from arteriosclerosis dislodged by guide catheter\textsuperscript{22-24}. In accordance with previous

Fig. 1. DW-MRI images in each patient with stroke after CAG.
A yellow arrow shows acute embolic lesion which was characterized by a bright hyperintense lesion on DW and ADC maps.
insufficiency was 3.8% \textsuperscript{31}. Furthermore, silent brain infarction is associated with a 2-fold increased risk of future stroke\textsuperscript{32}.

**Study Limitations**

There are several limitations in this study. First, the present study is an observational study; therefore, unknown risk factors may exist. However, we extracted detailed data as much as possible. Secondly, 61 cases from a single facility is a small sample size and statistically insufficient to investigate the risk factors of CVD. Further studies with large sample sizes are required. Finally, because the procedures, particularly the access site of the catheter, were not allocated in this study, we could not clarify the difference among the procedures.

**Conclusions**

The incidence of the asymptomatic CI detected by MRI after CAG was 9.8%, but no onset of symptomatic CI was observed. Only prior CABG was found to be an independent risk factor for the development of asymptomatic CI. We suggest that the incidence of CI after CAG was not related to the catheterization procedure per se but caused by severe atherosclerosis and multiple coronary stenosis in patients who underwent CABG.

**Acknowledgments**

The authors would like to acknowledge the valuable contribution of the staff of the catheter laboratory at Kagoshima University Hospital.

**Notice of Grant Support**

This research received no grants from funding agencies in the public, commercial or not-for-profit sectors.
Conflict of Interest

The authors declare that they have no conflicts of interest.

References

1) Adams DF, Abrams HL: Complications of coronary arteriography: a follow-up report. Cardiovasc Radiol, 1979; 2: 89-96
2) Bourassa MG, Noble J: Complication rate of coronary arteriography. A review of 5250 cases studied by a percutaneous femoral technique. Circulation, 1976; 53: 106-114
3) de Bono D: Complications of diagnostic cardiac catheterization: Results from 34,041 patients in the United Kingdom confidential enquiry into cardiac catheter complications. Br Heart J, 1993; 70: 297-300
4) Werner N, Bauer T, Hochadel M, Zahn R, Weidinger F, Marco J, Hamm C, Gitt AK, Zeymer U: Cardiac catheterization incidence and clinical impact of stroke complicating percutaneous coronary intervention. Circ Cardiovasc Interv, 2013; 6: 362-370
5) Hoffman SJ, Routledge HC, Lennon RJ, Mustafa MZ, Rihal CS, Gersh BJ, Holmes DR, Gulati R: Procedural factors associated with percutaneous coronary intervention-related ischemic stroke. JACC Cardiovasc Interv, 2012; 5: 200-206
6) Korn-Lubetzki I, Farkash R, Pachino RM, Almagor Y, Tzivoni D, Meerkin D: Incidence and risk factors of cerebrovascular events following cardiac catheterization. J Am Heart Assoc, 2013; 2: e000413
7) Ratib K, Mamas MA, Routledge HC, Ludman PF, Fraser D, Nolan J: Influence of access site choice on incidence of neurologic complications after percutaneous coronary intervention. Am Heart J, 2013; 165: 317-324
8) Hoffman SJ, Holmes DR, Rabinstein AA, Rihal CS, Gersh BJ, Lennon RJ, Bashir R, Gulati R: Trends, predictors, and outcomes of cerebrovascular events related to percutaneous coronary intervention: a 16-year single-center experience. JACC Cardiovasc Interv, 2011; 4: 415-422
9) Aggarwal A, Dai D, Rumsfeld JS, Klein LW, Roe MT: Incidence and Predictors of Stroke Associated With Percutaneous Coronary Intervention. Am J Cardiol, 2009; 104: 349-353
10) Büsing K, Schulte-Sasse C, Flüchter S, Süsselbeck T, Haase KK, Neff W, Hirsch JG, Borggrefe M, Dühber C: Cerebral infarction: incidence and risk factors after diagnostic and interventional cardiac catheterization—prospective evaluation at diffusion-weighted MR imaging. Radiology, 2005; 235: 177-183
11) Omran H, Schmidt H, Hackenbroch M, Illien S, Bernhardt P, von der Recke G, Fimmers R, Flacke S, Layer G, Pohl C, Lüderitz B, Schild H, Sommer T: Silent and apparent cerebral embolism after retrograde catheterization of the aortic valve in valvular stenosis: a prospective, randomised study. Lancet, 2003; 361: 1241-1246
12) Lund C, Nes RB, Ugelstad TP, Due-Tønnessen P, Andersen R, Hol PK, Brucher R, Russell D: Cerebral emboli during left heart catheterization may cause acute brain injury. Eur Heart J, 2005; 26: 1269-1275
13) Kim I-C, Hur S-H, Park N-H, Jun D-H, Cho Y-K, Nam C-W, Kim H, Han S-W, Choi S-Y, Kim Y-N, Kim K-B: Incidence and predictors of silent embolic cerebral infarction following diagnostic coronary angiography. Int J Cardiol, 2011; 148: 179-182
14) Dukkipati S, O’Neill WW, Harjai KJ, Sanders WP, Deo D, Boura JA, Bartholomew BA, Yerkey MW, Sadeghi HM, Kahn JK: Characteristics of cerebrovascular accidents after percutaneous coronary interventions. J Am Coll Cardiol, 2004; 43: 1161-1167
15) Fuchs S, Stabile E, Kinnaid TD, Mintz GS, Gruberg L, Canos DA, Pinnow EE, Kornowski R, Sudath WO, Satler LF, Pichard AD, Kent KM, Weissman NJ: Stroke complicating percutaneous coronary interventions: incidence, predictors, and prognostic implications. Circulation, 2002; 106: 86-91
16) Wong SC, Minutello R, Hong MK: Neurological complications following percutaneous coronary interventions (a report from the 2000-2001 New York State Angioplasty Registry). Am J Cardiol, 2005; 96: 1248-1250
17) Scanlon PJ, Faxon DP, Audet A-M, Carabello B, Dehmer GJ, Eagle KA, Legako RD, Leon DF, Murray JA, Nissen SE, Pepine CJ, Watson RM, Ritchie JL, Gibbons RJ, Cheitlin MD, Eagle KA, Gardner TJ, Garson A, Russell RO, Ryan TJ, Smith SC: ACC/AHA guidelines for coronary angiography. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on Coronary Angiography). Developed in collaboration with the Society for Cardiac Angiography and Interventions. J Am Coll Cardiol, 1999; 33: 1756-1824
18) Nishimura RA, Otto CM, Bonow RO, Carabello BA, Li JPE, Guyton RA, Gara PTO, Ruiz CE, Skubas NJ, Sora-P, Thoralf M, Li J, Thomas JD: 2014 AHA/ACC Guideline for the management of patients with valvular heart disease: executive summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation, 2014; 129: e650
19) Agresti A, Coull BA: Approximate is better than “exact” for interval estimation of binomial proportions. Am Sta, 1998; 52: 119-126
20) Büsing KA, Schulte-Sasse C, Flüchter S, Süsselbeck T, Haase KK, Neff W, Hirsch JG, Borggrefe M, Dühber C: Cerebral infarction: incidence and risk factors after diagnostic and interventional cardiac catheterization—prospective evaluation at diffusion-weighted MR imaging. Radiology, 2005; 235: 177-183
21) Morita Y, Kato T, Okano M, Suga K, Kimura M, Minamino-Muta E, Nakane E, Izumi T, Miyamoto S, Haruna T, Ueyama K, Inoko M: Incidence and predictors of catheterization-related cerebral infarction on diffusion-weighted magnetic resonance imaging. Biomed Res Int, 2016; 2016
22) Karalis DG, Quinn V, Victor MF, Ross JJ, Polansky M, Spratt KA, Chandrasekaran K: Risk of catheter-related emboli in patients with atherosclerotic debris in the thoracic aorta. Am Heart, 1996; 131: 1149-1155
23) Bracken SK, Endresen K, Russell D, Brucher R, Kjekshus J: Influence of guidewire and catheter type on...
the frequency of cerebral microembolic signals during left heart catheterization. Am J Cardiol, 1998; 82: 632-637

24) Keeley EC, Grines CL: Scraping of aortic debris by coronary guiding catheters: a prospective evaluation of 1,000 cases. J Am Coll Cardiol, 1998; 32: 1861-1865

25) Hamon M, Lipiecki J, Carri D, Burzotta F, Durel N, Coutance G, Boudou N, Colosimo C, Trani C, Dumonteil N, Morello R, Viader F, Claire B, Hamon M: Silent cerebral infarcts after cardiac catheterization: a randomized comparison of radial and femoral approaches. Am Heart J, 2012; 164: 449-454

26) Guptill JT, Mehta RH, Armstrong PW, Horton J, Laskowitz D, James S, Granger CB, Lopes RD: Stroke after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction timing, characteristics, and clinical outcomes. Circ Cardiovasc Interv, 2013; 6: 176-183

27) Kwok CS, Kontopantelis E, Myint PK, Zaman A, Berry C, Keavney B, Nolan J, Ludman PF, de Belder MA., Buchan I, Mamas MA: Stroke following percutaneous coronary intervention: type-specific incidence, outcomes and determinants seen by the British Cardiovascular Intervention Society 2007–12. Eur Heart J, 2015; 36: 1618-1628

28) Vermeer SE, Longstreth WT, Koudstaal PJ: Silent brain infarcts: a systematic review. Lancet Neurol, 2007; 6: 611-619

29) Hoshide S, Kario K, Mitsuhashi T, Sato Y, Umeda Y, Katsuki T, Shimada K: Different patterns of silent cerebral infarct in patients with coronary artery disease or hypertension. Am J Hypertens, 2001; 14: 509-515

30) Uekita K, Hasebe N, Funayama N, Aoyama H, Kuroda K, Aizawa H, Kataoka R, Kikuchi K: Cervical and intracranial atherosclerosis and silent brain infarction in Japanese patients with coronary artery disease. Cerebrovasc Dis, 2003; 16: 61-68

31) Naito R, Miyauchi K, Shitara J, Endo H, Wada H, Doi S, Konishi H, Tsuboi S, Ogita M, Dohi T, Kasai T, Tamura H, Okazaki S, Isoda K, Daida H: Temporal trends in clinical outcomes following percutaneous coronary intervention in patients with renal insufficiency. J Atheroscler Thromb, 2016; 23: 1080-1088

32) Gupta A, Giambrone AE, Gialdini G, Finn C, Delgado D, Gutierrez J, Wright C, Beiser AS, Seshadri S, Pandya A, Kamel H: Silent brain infarction and risk of future stroke: a systematic review and meta-analysis. 2016; 47: 719-725